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Abstract
As part of an effort to identify agonists of TRPV1, a peripheral sensory nerve ion channel, high 
throughput screening of the NIH Small Molecule Repository (SMR) collection identified 
MLS002174161, a pentacyclic benzodiazepine. A synthesis effort was initiated that ultimately 
afforded racemic seco analogs 12 of the SMR compound via a silver mediated intramolecular 
[3+2] cycloaddition of an azo-methine ylide generated from α-iminoamides 11. The cycloaddition 
set four contiguous stereocenters and, in some cases, also spontaneously afforded imides 13 from 
12. The synthesis of compounds 12, the features that facilitated the conversion of 12–13, and their 
partial agonist activity against TRPV1 are discussed.
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One of the most problematic areas in contemporary clinical practice is the long-term 
management of chronic pain. There are numerous analgesics available for this purpose, 
many of which act at the opioid receptors in the CNS.1 While these drugs are safe and 
effective if administered under rigorously controlled conditions, long-term use of opiates 
inevitably leads to tolerance, physical dependence and sometimes depression.1 More 
troublesome, however, is that the mood altering effects of opiates are such that, under real 
life conditions, these medications are often diverted and abused. The resultant social and 
economic consequences of these drawbacks are a source of continuing concern.2
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As an alternative to opiates, peripherally-acting agents, of whom NSAIDS are the most 
familiar examples, have been less useful when pain is in the moderate to severe range.3 
Peripheral agents act by altering molecular and physiological events at the site where the 
pain signal is generated instead of where the signal is received or perceived in the CNS.4 In 
doing so, peripheral agents present a major advantage in that they do not alter 
consciousness, do not produce other deleterious CNS side effects nor do they interfere with 
the analgesic actions of centrally-acting agents such as opiates. Despite these advantages, 
available peripheral agents have not demonstrated efficacy as replacements for centrally 
acting agents. Currently known peripheral analgesics do not block the initiation of pain 
signals with the specificity and to the extent required for the improvement in the quality of 
life of chronic pain patients.
The initial step of pain sensation is the generation of action potential( s) by ion channel 
mediated depolarization of sensory nerve terminals in skin or deep tissues.5 Preventing the 
generation of these nociceptive signals at their origin by inhibiting the ion channels 
responsible for the depolarization would provide highly effective analgesia since a pain 
signal that is not generated is one that requires no blockage further upstream in the CNS. 
However, there are a multitude of ion channels in nociceptive nerve endings that can 
respond to algesic chemicals released from damaged cells. For this reason blocking only one 
channel does not appear to provide the efficacy necessary for a useful analgesic agent. 
Alternatively, it may be possible to administer an agent that will temporarily disable the 
nociceptive nerve endings but only in the localized areas directly implicated in the painful 
condition, essentially acting as a highly specific, activity dependent long-term analgesic.
TRPV1 is a high-conductance, non-specific cation channel both restricted to and highly 
expressed in a subpopulation of nociceptive afferents. The receptor is activated by small-
molecule ligands, noxious heat (>42 °C) and extracellular protons, contributing to pain 
sensation under pathological conditions like chronic inflammation (arthritic pain) or 
chemotherapy-induced and diabetic neuropathies.6 Initial enthusiasm to develop small-
molecule antagonists of TRPV1 that bind at the capsaicin recognition site as a novel class of 
analgesics to ‘block pain at the source’ faded as side effects stemming from less-studied 
physiological roles of TRPV1 emerged during clinical trials.7
As an alternative to antagonists, we have been working on the development of both potent 
agonists and positive allosteric modulators (PAMs) of TRPV1 as analgesic agents. Both can 
temporarily incapacitate TRPV1 expressing nerve terminals through calcium overload. 
Potent agonists like resiniferatoxin (RTX) affect all TRPV1 positive nerve endings, while 
PAMs act only at nerve terminals with activated TRPV1, in a state-dependent manner.8 
Local administration of potent TRPV1 agonists or oral administration of TRPV1 PAMs 
could provide a new class of analgesics and a much sought-after alternative to opioids in 
pain control. Designing or discovering such agents could be rendered more facile with 
increased understanding of the structure of the relevant ion channels. The structure of 
TRPV1 has not yet been solved and, in an effort to acquire understanding of its structure and 
pharmacology, a screening program was undertaken to identify either agonists or allosteric 
modulators.
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A high-throughput screen of the NIH Small Molecule Repository (SMR) revealed a series of 
geometrically constrained TRPV1 agonists, possessing structural features reminiscent of 
capsaicin, with compound MLS002174161 showing highest potency (Fig. 1).9 In order to 
better understand the spatial organization of the TRPV1 agonist pharmacophore responsible 
for the activity of MLS002174161, a series of related compounds was proposed for 
synthesis and SAR study. Given the structure, we believed that closely related compounds 
could be prepared using a method similar to that of Grigg and used later by Kurth, followed 
by modifications at the nitrogen atom and ester (Scheme 1).10 In this sequence phenol 1a 
was first alkylated with commercially available ethyl trans-4-bromo-2-butenoate to afford 
2a in 49% yield.11 Aldehyde 2a was next converted to imines 3a and 3b through reaction 
with the methyl or benzyl esters of alanine HCl salt in the presence of Hünig’s base and 4 Å 
molecular sieves. From here, the imines 3a and 3b were converted to their corresponding 
cycladducts 4a and 4b in 55% and 44% yields, respectively. The cycloadducts were 
obtained as single diastereomers, with the relative configurations shown, as described in 
earlier reports. The cycloadducts 4 were racemic regardless of whether or not chiral alanine 
esters were used.10
Attempts to acylate the secondary nitrogen atom using aromatic acyl chlorides to afford 
various amides were not successful. We were, however, able to prepare the related 
hydantoins 6a and 6b using methyl ester 4a by reaction with aryl isocyantes followed by 
intramolecular ring closure in a manner similar to Kurth’s example (Scheme 2).10b This 
observation led us to conclude that only the most reactive and unhindered electrophiles can 
react with this particular nitrogen atom. Again, the stereochemistry is implied from the 
previous reports, although Kurth notes epimerization at the α-position to the methyl ester 
occurs under the basic conditions employed for ring closure of glycine derivatives. In our 
alanine derived case, the presence of the additional methyl group prevents epimerization.
After encountering more difficulties in diversifying the α-methyl substituted ester group in 
4a and 4b a new strategy was employed in which the amide portion was preassembled prior 
to imine formation (Scheme 3). The resultant α-iminoamides 11 could then be subjected to 
the 1,3-dipolar cycloaddition conditions to afford the desired amide compounds in a 
convergent fashion. To the best of our knowledge, there have been few reports of α-
iminoamides being used in this type of azo-methine ylide 1,3-dipolar cycloaddition, with 
most examples appearing as part of a larger series that contain mostly esters.12 Only one 
report, published in 2012, focuses exclusively on this class of substrates.13 Of all the 1,3-
dipolar cycloaddition reactions of α-iminoamides found, we encountered no intramolecular 
examples.
We first needed to synthesize a suitable α-aminoamide. For reasons related to our previous 
initial screening study, we wished to couple aniline derivative 8a to Bocalanine, affording 
9a. This was accomplished (Scheme 3) with EEDQ being crucial to the coupling. 14 
Microwave irradiation accelerated the reaction, conveniently providing 9a in 73% yield. 
These microwave conditions were adopted for the formation of all subsequent α-
aminoamides described in this report. To finish the sequence, TFA salt 10a was formed by 
deprotection of 9a. The conditions shown in Scheme 1 were then used to form α-
iminoamide 11a in 76% yield from 9a. Effecting the cycloaddition reaction as in Scheme 1 
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was unsuccessful due to the low solubility of α-iminoamide 11a in acetonitrile. The reaction 
was therefore performed in dichloromethane (DCM) using silver fluoride and 
triethylamine.15 These conditions afforded the desired product 12a in 22% yield, but also 
provided a second product which was, by 1H NMR spectroscopy, a mixture of two other 
compounds that showed the absence of the ethyl ester group. LCMS analysis, which showed 
a single compound, also showed the loss of ethanol from the mass of the cycloadduct 12a. 
As a result of variable temperature 1H NMR spectroscopy coalescence studies and 15N 
NMR spectroscopy we assigned the structure of the second product to be imide 13a (29% 
yield) as a 2:1 mixture of atropisomers. Using the less basic silver trifluoroacetate in place 
of silver fluoride also afforded the same products, but gave 13a in a diminished 13% yield.
To probe the scope and limitations of this method and provide some initial SAR, a series of 
α-aminoamides and aldehydes was synthesized using the above conditions (Scheme 4).
Deprotection of N-Boc-protected α-aminoamides 9 provided their α-aminoamide TFA salts 
(corresponding to Scheme 3, structure 10). These TFA salts were combined with aldehydes 
2 under the conditions shown in Scheme 3 to provide the desired imines 11 in 58–92% 
yields in all but one case (Table 1).
Imines 11b, c, d, and e, derived from 9a and aldehydes 2b, c, d and e, underwent AgF 
promoted cyclization as shown in Scheme 3 to afford mixtures of cycloadducts 12b–e and 
their derived imides 13b–e. Cycloadducts 12b–e were formed in 19–22% yield and imides 
13b–e in 23–36% yield, respectively (Table 1, entries 1–4).16 Imine 11f (R1 = H), obtained 
from aldehyde 2a and glycine derived α-aminoamide 9e, gave cycloadduct 12f (14% yield) 
and imide 13f (28% yield; Table 1, entry 5). We observed, qualitatively, that the conversion 
of glycine derived 12f to imide 13f was more facile than the conversion of alanine derived 
12a to imide 13a. Cycloadduct 12f was isolated in pure form by normal phase 
chromatography. However, during reverse phase HPLC analysis or purification of 12f, using 
an aq ammonia (pH 9.4) modified mobile phase, imide 13f was generated. Imide 13f did not 
form under acidic conditions. This apparent ammonia promoted imide formation was not 
observed for any of the alanine derived compounds.
To shed some light on the structural features that facilitate the conversion of cycloadducts 
12 to imides 13, alanine derived α-aminoamides 9b, 9c and 9d were used to form imines 
11g, 11h and 11i from aldehyde 2a. Imines 11g and 11h were synthesized in 83% and 75% 
yields respectively and subjected to the silver-mediated cyclization conditions (Table 1, 
entries 6 and 7). 9d failed to form imine 11i (Table 1, entry 8).
We initially hypothesized that the electron-withdrawing aryl ortho-carboxymethyl 
substituent facilitated the conversion of cycloadducts 12 to imides 13 solely by lowering the 
pKa of the anilide proton just enough that some polarization of the N–H bond would occur. 
The bond polarization would increase the negatively charged character of the nitrogen and 
lead to imide formation. In keeping with this idea, we were not surprised that 11g did not 
undergo this process, giving only cycloadduct 12g (20% yield; Table 1, entry 6) with no 
accompanying formation of imide 13g. We then predicted that the para-carboxymethyl 
substituent of 11h would exert a similar effect, giving first cycloadduct 12h and then imide 
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13h. This did not occur. Aryl para-carboxymethyl 11h gave only cycloadduct 12h (44% 
yield; Table 1, entry 7) without spontaneously affording the imide 13h. This did not support 
our ‘pKa lowering’ hypothesis. Another experiment using aryl orthoethyl species 11j was 
carried out (Table 1, entry 9). The electronically neutral, but sterically congested, ortho-
ethyl 11j also stopped reacting at the initial cycloadduct stage, giving 12j (28% yield) 
without formation of imide 13j. Thus only the electron-withdrawing, sterically congested 
ortho-esters afforded imides. We concluded that both of the preceding factors are needed to 
convert the cycloadducts 12 to the imides 13.
Two fully N-substituted α-iminoamides 11k (from α-N-Bocaminoamide 9f and aldehyde 2a) 
and 11n (from α-N-Boc-aminoamide 9g and aldehyde 2d) were also prepared and subjected 
to AgF promoted cyclization. Alanine derived imine 11k failed to afford any cycloadduct or 
imine products (Table 1, entry 10). Glycine derived imine 11n afforded cycloadduct 12n in 
42% yield with no imine 13n formed (Table 1, entry 11). We believe A1,3 strain that is 
present in the formation of the azo-methine intermediate in Int-11k prevents the 
cycloaddition reaction from easily occurring. This strain would not be present in the case of 
Int-11n or when employing a secondary amide such as shown by Int-11a (Scheme 5).
Finally, to assess the accuracy of our assignments of relative stereochemistry with respect to 
the cycloadducts that were obtained using the α-iminoamides cycloadduct 12n, purified to 
>99 area% as analyzed by High Resolution LCMS, was crystallized from 0.1 N HCl. The 
crystallization afforded two crystal forms: a triclinic unit cell as a needle and a monoclinic 
unit cell as a plate. X-ray crystallographic data for the plate was obtained (deposition 
#CCDC 972332), showing the product as its monohydrate with the relative stereochemistry 
we expected based on Kurth’s precedent (Fig. 2). The needles were not characterized by X-
ray.
The synthesized compounds 4a, 6a, 6b, 12a–h, 12j, 12n, 13a–f were assayed for TRPV1 
agonist activity. The activity of the above compounds that showed agonist properties is 
shown in Fig. 3. Four compounds, 12a, 12e, 12b and 12d showed partial agonism.
The structures of all the compounds tested can be classified into three main categories based 
on the scheme proposed by Walpole (refer to the above color-coded region structure of 
capsaicin, Fig. 1A).8 Compound 4a falls into the first group. This compound lacks the 
benzyl group corresponding to region ‘A’ in Walpole’s scheme, resulting in the expected 
loss of agonist activity. Group 2 consists of compounds displaying the benzyl moiety 
together with an additional methyl-, carboxymethyl group, or both (compounds 12a, 12g, 
12e, 12c, 12b, 12h, 12d, 12f and 12n). In addition, the nitrogen adjacent to the benzyl ring 
forms an amide bond, showing good correspondence to the ‘B’ region of capsaicin. The 
third group consists of compounds where the nitrogen adjacent to the benzyl group is 
incorporated into either a hydantoin ring or an imide ring and ceases to behave as a 
hydrogen bond donor (compounds 13a, 6a, 6b, 13e, 13c, 13b, 13d and 13f), while also 
reducing their flexibility.
All TRPV1 agonists identified (12a, 12e, 12b and 12d) belong to the second group. Their 
structure relative to capsaicin and their lower potency align well with observations made by 
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Walpole: (1) removing the single sp3 carbon ‘spacer’ separating the benzyl group from the 
amide group results in a ten-fold reduction of potency {3a–b, Table 1, Walpole region ‘B’ 
1993} (2) eliminating the H-bond donor nitrogen from the amide bond also takes a 
significant toll on potency {3a vs 20, Table 1, Walpole region ‘B’ 1993} (3) additional 
groups on the benzyl ‘A’ region are far from the optimal 4-Hydroxy 3-methoxy groups 
found in capsaicin {2b, Table 1, Walpole region ‘A’, 1993}.
Conclusions
We have identified a novel, spatially constrained, TRPV1 agonist and four seco analogs with 
partial TRPV1 agonist activity. Using the alignment of the active analogs, capsaicin and the 
fully rigid agonist MLS002174161, we propose a three-dimensional TRPV1 agonist 
pharmacophore comprised of aromatic, hydrophobic, hydrogen-bond donor and acceptor 
moieties, complete with directional information about the expected locations of donor and 
acceptor partners. We expect that, following further validation, the above proposed 
pharmacophore model will facilitate the development of potent TRPV1 agonists with 
potential use in the treatment of localized, chronic pain.
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High-throughput screen identified a constrained TPRV1 agonist. (A) Structure of capsaicin, 
archetypical vanilloid TRPV1 agonist. Color coding highlights structural subdivision 
according to Walpole, 1993 (red = region A, blue = region B, green = region C) (B) 
MLS002174161, a fully constrained rigid TRPV1 agonist with proposed alignment of 
capsaicin (C) MLS002174161 is a full agonist of TRPV1 with reduced potency compared to 
capsaicin. This reduction of potency is expected due to the rigidity of the ligand.
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X-ray crystal structure of 12n as its monohydrate.
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Biological activity of synthesized compounds on TRPV1 using a 45Ca2+ uptake assay. (A) 
Four out of the eighteen compounds exhibited TRPV1 agonist activity. Compounds 12a, 
12e, 12b and 12d all behave as partial TRPV1 agonists with 12e showing the lowest potency 
and efficacy. (B) Proposed alignment of capsaicin (cyan), MLS002174161 (salmon) and the 
four partial agonists (light grey). The proposed alignment shows good overlap of an 
Aromatic center (orange) and a Hydrophobic region (green) between all compounds. They 
also exhibit closely localized hydrogen-bond Donor (pink) and Acceptor (blue) groups and 
similarly tight grouping of hydrogen-bond donor and acceptor projections (Don2 (dark cyan) 
and Acc2 (grey), respectively).
Painter et al. Page 11














Synthesis of the initially proposed ester scaffolds.
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Synthesis of hydantoins 6.
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Synthetic sequence for formation of 12a and 13a.
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Synthesis α-aminoamides and aldehydes.
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Proposed A1,3 Strain of 1,3-dipole Int-11k vs. Int-11a and Int-11n.
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